
Liked By
Spread the love. Be the first to like this post!
Recent OMER News
- Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) • Edgar (US Regulatory) • 11/18/2022 11:04:28 AM
- Maxim Group Keeps Their Hold Rating on Omeros (OMER) • TipRanks • 11/16/2022 08:25:07 PM
- Needham Reaffirms Their Hold Rating on Omeros (OMER) • TipRanks • 11/10/2022 11:25:31 AM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 11/09/2022 09:07:51 PM
- Omeros Corporation Reports Third Quarter 2022 Financial Results • Business Wire • 11/09/2022 09:02:00 PM
- Omeros Corporation Receives Decision from FDA on Formal Dispute Resolution Request for Narsoplimab • Business Wire • 11/08/2022 01:30:00 PM
- Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2022 • Business Wire • 11/04/2022 01:00:00 PM
- Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting • Business Wire • 11/03/2022 01:00:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 10/06/2022 08:43:55 PM
- Omeros Corporation Announces Royalty Monetization Transaction with DRI Healthcare Trust • Business Wire • 10/03/2022 11:10:00 AM
- Omeros (NASDAQ:OMER) Tanks on COVID-19 Therapy Data • TipRanks • 09/15/2022 02:39:04 PM
- Omeros Corporation Reports Narsoplimab Treatment Results in Critically Ill COVID-19 Patients in I-SPY COVID Trial • Business Wire • 09/15/2022 01:06:00 PM
- I-SPY COVID Trial Sponsored by Quantum Leap Healthcare Collaborative Reports Assessment of Narsoplimab for Treatment of Critically Ill Patients With COVID-19 • Business Wire • 09/15/2022 01:02:00 PM
- Omeros Corporation Receives Interim Response from FDA on Formal Dispute Resolution Request for Narsoplimab • Business Wire • 08/17/2022 12:40:00 PM
- Maxim Group Keeps Their Hold Rating on Omeros (OMER) • TipRanks • 08/13/2022 04:05:14 PM
- Quarterly Report (10-q) • Edgar (US Regulatory) • 08/09/2022 08:20:12 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 08/09/2022 08:12:33 PM
- Omeros Corporation Reports Second Quarter 2022 Financial Results • Business Wire • 08/09/2022 08:02:00 PM
- Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2022 • Business Wire • 08/04/2022 12:30:00 PM
- Omeros Gets FDA Orphan-Drug Designation for OMS906 in PNH • Dow Jones News • 07/29/2022 01:25:00 PM
- FDA Grants Orphan Drug Designation to Omeros’ MASP-3 Inhibitor OMS906 for Treatment of Paroxysmal Nocturnal Hemoglobinuria • Business Wire • 07/29/2022 12:45:00 PM
- Statement of Ownership (sc 13g) • Edgar (US Regulatory) • 07/08/2022 08:59:30 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 06/22/2022 09:25:57 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 06/22/2022 09:25:11 PM
- Omeros Announces Webcast Details for Annual Meeting of Shareholders • Business Wire • 06/15/2022 12:00:00 PM
TNRG Signs Reg A Offering Agreement • TNRG • Feb 3, 2023 10:30 AM
Trend Innovations Holding Inc. Thy News Application Review Year 2022 and Update Toward 2023 • TREN • Feb 2, 2023 2:00 PM
Goldshore Intersects 9.46 g/t Au over 7.45m in the Southwest Zone Widths of Mineralized System Expanded Significantly. • GSHRF • Feb 2, 2023 9:58 AM
Hempacco and Snoop Dogg Create Joint Venture to Launch Consumer Goods Powerhouse of Hemp and Hemp-Derived Products • HPCO • Feb 2, 2023 9:30 AM
Kona Gold Beverage, Inc Announces Record Revenue Month in January Eclipsing Half a Million Dollars for the First Time • KGKG • Feb 2, 2023 9:00 AM
BioLife Sciences Inc. (OTC: BLFE) Announces Letter of Intent for Exclusive Licensing Deal with Canadian Firm • BLFE • Feb 2, 2023 8:32 AM